Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model

Fig. 5

Kinetics of expansion of (A) leukemia, (B) NK1.1+, (C) CD4+, (D) CD8+, (E) NK1.1+GrzB+, (F) CD4+GrzB+, and (G) CD8+GrzB+ cells in the peritoneum of mice injected with IL-15 secreting leukemia cells. Every graph shows a time course, and every time point has been obtained by sacrificing 3–6 mice/group. Numbers shown are total cell numbers calculated based on the absolute cell numbers obtained by peritoneal lavage. Naïve mice were included to obtain baseline levels and were included on the graph on the day they were analyzed. Experiments have been performed three times with similar results, and were pooled. For statistical analysis peak values on day 8 were compared within groups using 1-way ANOVA (see Table 2 for statistical analysis). a GFP+70Z/3-L parent strain expands significantly more in vivo than LV15Rc or LV-15sol secreting line. b NK1.1+ cells expand significantly more in mice injected with LV15Rc.4 compared to all other groups. c CD4+ cells expand significantly more in mice injected with LV15sol.1 compared to all other groups. d CD8+ cells expand significantly more in mice injected with LV15sol.1 vs LV15Rc.4. e The increase of NK1.1+GrzB+ cells in the peritoneum of mice injected with LV15Rc.4 was significantly higher compared to LV15sol.1 (p = 0.0147, day 8); f The total numbers of CD4+GrzB+ cells in the peritoneum of mice injected with LV15sol.1 were significantly higher compared to LV15Rc.4 (p = 0.0070, day 8). g The total numbers of CD8+GrzB+ cells in the peritoneum of mice injected with LV15sol.1 were significantly higher compared to LV15Rc.4 (p = 0.0171, day 8)

Back to article page